Human medicines European public assessment report (EPAR): Rapamune, sirolimus, Date of authorisation: 13/03/2001, Revision: 49, Status: Authorised

Human medicines European public assessment report (EPAR): Pemetrexed Pfizer (previously Pemetrexed Hospira), pemetrexed, Date of authorisation: 19/11/2015, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Mylotarg, gemtuzumab ozogamicin, Date of authorisation: 19/04/2018, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Levetiracetam Hospira, levetiracetam, Date of authorisation: 07/01/2014, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Elrexfio, elranatamab, Date of authorisation: 07/12/2023, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Daptomycin Hospira, daptomycin, Date of authorisation: 22/03/2017, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Besponsa, inotuzumab ozogamicin, Date of authorisation: 28/06/2017, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Emblaveo, aztreonam,avibactam, Date of authorisation: 22/04/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Attrogy, diflunisal, Date of authorisation: 17/07/2025, Status: Authorised

EU Implementation Guide (IG) on veterinary medicines product data in the Union Product Database - Chapter 2: Format for the electronic submission of veterinary medicinal product information